At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
In Brief
A Phase 2 clinical trial evaluating Radiation and Pembrolizumab for Adenoid Cystic Carcinoma. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma. The immunotherapy involved in this study is: * Pembrolizumab (MK-3475 or KEYTRUDA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenoid Cystic Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartApr 2017
Primary CompletionAug 2020
TodayJul 2026
First PostedMar 22, 2017
Enrollment StartApr 25, 2017
Primary CompletionAug 4, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.3 years ago
Interventions
Radiationradiation
Standard use of radiation is administered
Pembrolizumabdrug
Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.